29th May 2015 06:41
LONDON (Alliance News) - AstraZeneca PLC said Friday it is collaborating with Eli Lilly and Co for a phase I study of AstraZeneca's MEDI4736 in combination with Lilly's ramucirumab as a treatment for patients with advanced solid tumours.
The phase I study is expected to establish the safety and recommended dosing regimen for a combination, with the potential to open up the combination for various tumours of interest, AstraZeneca said. The trial will be sponsored by Lilly.
"MEDI4736 is supported by a comprehensive development programme and is emerging as a cornerstone of our combination-focused immuno-oncology pipeline targeting multiple tumour types. Our collaboration with Lilly is a great addition to our programme and provides the opportunity to explore another exciting, novel combination that could deliver important clinical benefit to cancer patients," said Robert Iannone, AstraZeneca's head of immuno-oncology, global medicines development in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca